Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ProMIS Neurosciences ( (PMN) ) just unveiled an announcement.
On October 22, 2025, ProMIS Neurosciences announced the appointment of Slanix Paul Alex, Pharm.D., to its Board of Directors, effective immediately. Dr. Alex brings extensive experience in healthcare investment and biotechnology equity research, which is expected to enhance ProMIS’s strategic vision and investor engagement as it progresses its Alzheimer’s program, PMN310. His appointment is seen as a strategic move to strengthen ProMIS’s board and support the company’s advancement towards late-stage clinical development, with key data readouts anticipated in 2026 from its PRECISE-AD trial.
The most recent analyst rating on (PMN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on ProMIS Neurosciences stock, see the PMN Stock Forecast page.
Spark’s Take on PMN Stock
According to Spark, TipRanks’ AI Analyst, PMN is a Underperform.
ProMIS Neurosciences faces significant financial hurdles, with no current revenue and ongoing operational losses, leading to a weak overall financial performance. The technical analysis indicates the stock is under pressure, and the valuation reflects challenges with a negative P/E ratio. While recent corporate events show promise in terms of future growth potential, they do not offset the immediate financial challenges. The overall score reflects the need for cautious optimism, as the company must improve its financials and achieve sustainable revenue generation.
To see Spark’s full report on PMN stock, click here.
More about ProMIS Neurosciences
ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing next-generation therapies for neurodegenerative disorders, including Alzheimer’s disease. The company utilizes its proprietary EpiSelect™ platform to identify novel targets on misfolded proteins, aiming to create therapeutic antibodies and vaccines that selectively target these proteins. ProMIS is advancing its lead product candidate, PMN310, which is designed to treat Alzheimer’s disease by targeting toxic oligomers.
Average Trading Volume: 1,629,642
Technical Sentiment Signal: Strong Sell
Current Market Cap: $22.75M
Find detailed analytics on PMN stock on TipRanks’ Stock Analysis page.